TRANSCATHETER DELIVERY OF C-MYC ANTISENSE OLIGOMERS REDUCES NEOINTIMAL FORMATION IN A PORCINE MODEL OF CORONARY-ARTERY BALLOON INJURY

被引:209
作者
SHI, Y [1 ]
FARD, A [1 ]
GALEO, A [1 ]
HUTCHINSON, HG [1 ]
VERMANI, P [1 ]
DODGE, GR [1 ]
HALL, DJ [1 ]
SHAHEEN, F [1 ]
ZALEWSKI, A [1 ]
机构
[1] THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DIV CARDIOL, PHILADELPHIA, PA 19107 USA
关键词
C-MYC; PROTOONCOGENES; SMOOTH MUSCLE CELLS; ANTISENSE OLIGOMERS; EXTRACELLULAR MATRIX; RESTENOSIS;
D O I
10.1161/01.CIR.90.2.944
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Smooth muscle cell proliferation and extracellular matrix accumulation are the principal mechanisms leading to vascular restenosis. We have previously demonstrated the growth-inhibitory effect of antisense oligomers targeting the c-myc proto-oncogene in human smooth muscle cells. The goal of this study was to investigate whether c-myc antisense oligomers reduce neointimal formation in balloon-denuded porcine coronary arteries. Methods and Results First, type I collagen synthesis, which reflects synthetic function, was markedly reduced following c-myc antisense oligomers in porcine vascular smooth muscle cells independent of the growth inhibition. These effects in vitro provided the rationale for assessing c-myc antisense oligomers in the prevention of neointima in vivo. Second, the efficiency of single transcatheter delivery of oligomers into denuded porcine coronary arteries was determined. Despite rapid plasma clearance following local delivery, oligomers persisted at the site of injection for at least 3 days, exceeding by severalfold their concentration in peripheral organs. Third, morphometric analyses were carried out in balloon-denuded coronary arteries at 1 month after transcatheter c-myc antisense oligomer administration. Maximal neointimal area was reduced from 0.80+/-0.17 mm(2) in the control group (n=12) to 0.24+/-0.06 mm(2) in the antisense-treated group (n=13, P<.01). Likewise, a significant reduction in maximal neointimal thickness was observed in the antisense-treated group (P<0.1). These changes in vascular remodeling following denuding injury resulted in an increase in residual lumen from 64+/-6% in the control group to 81+/-5% in the antisense-treated group (P<.05). Conclusions (1) Single transcatheter administration allowed for endoluminal delivery of oligomers to the site of coronary arterial injury. (2) C-myc antisense oligomers reduced the formation of neointima in denuded coronary arteries, implying a therapeutic potential of this approach for the prevention of coronary restenosis. (3) It is postulated that the c-myc proto-oncogene is involved in the process of vascular remodeling, regulating smooth muscle cell proliferation and extracellular matrix synthesis.
引用
收藏
页码:944 / 951
页数:8
相关论文
共 47 条
  • [11] CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329
  • [12] ORGAN DISTRIBUTION AND STABILITY OF PHOSPHOROTHIOATED OLIGODEOXYRIBONUCLEOTIDES IN MICE
    GOODARZI, G
    WATABE, M
    WATABE, K
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 1992, 13 (03) : 221 - 227
  • [13] SPECIFIC REGULATION OF GENE-EXPRESSION BY ANTISENSE, SENSE AND ANTIGENE NUCLEIC-ACIDS
    HELENE, C
    TOULME, JJ
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1049 (02) : 99 - 125
  • [14] IVERSEN P, 1991, ANTI-CANCER DRUG DES, V6, P531
  • [15] ACTIVATION AND REPRESSION OF MAMMALIAN GENE-EXPRESSION BY THE C-MYC PROTEIN
    KADDURAHDAOUK, R
    GREENE, JM
    BALDWIN, AS
    KINGSTON, RE
    [J]. GENES & DEVELOPMENT, 1987, 1 (04) : 347 - 357
  • [16] KINDY MS, 1988, J BIOL CHEM, V263, P11426
  • [17] EVIDENCE IMPLICATING NONMUSCLE MYOSIN IN RESTENOSIS - USE OF INSITU HYBRIDIZATION TO ANALYZE HUMAN VASCULAR-LESIONS OBTAINED BY DIRECTIONAL ATHERECTOMY
    LECLERC, G
    ISNER, JM
    KEARNEY, M
    SIMONS, M
    SAFIAN, RD
    BAIM, DS
    WEIR, L
    [J]. CIRCULATION, 1992, 85 (02) : 543 - 553
  • [18] PRODUCTION OF TRANSFORMING GROWTH FACTOR-BETA-1 DURING REPAIR OF ARTERIAL INJURY
    MAJESKY, MW
    LINDNER, V
    TWARDZIK, DR
    SCHWARTZ, SM
    REIDY, MA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (03) : 904 - 910
  • [19] MIANO JM, 1990, AM J PATHOL, V137, P761
  • [20] CURRENT CONCEPTS IN ANTISENSE DRUG DESIGN
    MILLIGAN, JF
    MATTEUCCI, MD
    MARTIN, JC
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (14) : 1923 - 1937